By applying pSILAC to the potent anti-cancer therapeutic lenalidomide, we demonstrate that a single time point experiment could identify ZFP91 as novel lenalidomide-dependent CRL4CRBN substrate. The gene discussed is ZFP91; the disease is cancer.